Genetic carrier screening: what it checks and what the results mean
Carrier screening is a genetic test that shows whether you carry a gene change for certain genetic conditions. Done before or during pregnancy, it shows the chance of having a child with one of those conditions. (ACOG FAQ, 2026) Your doctor decides what your result means for you.
How carrier screening works
- The sample: blood, saliva or tissue from the inside of the cheek. (ACOG FAQ, 2026)
- What a carrier is: someone who carries one copy of a gene change that causes a genetic condition when present in two copies. (MedlinePlus Genetics, 2021) Carriers usually have no symptoms or only mild ones, and often do not know. (ACOG FAQ, 2026)
- Recessive conditions: most carrier screening is for these. A child has the condition only by getting a changed gene from each parent. (ACOG FAQ, 2026)
- When: before pregnancy or during it. ACOG says screening and counseling ideally come before pregnancy, and the ACMG says preconception screening is recommended over prenatal screening. (ACOG CO 691, 2017) (ACMG, 2021)
- Your choice: screening is optional, and a person may decline any or all of it. (ACOG FAQ, 2026) (ACOG CO 691, 2017)
- Once is enough for each condition: ACOG says that after screening for a specific condition you do not need to be screened for it again. (ACOG FAQ, 2026) The ACMG says screening should be looked at again when the reproductive partner changes, and that someone who had a shorter panel in an earlier pregnancy should be offered its Tier 3 screening. (ACMG, 2021)
What it checks
| Condition | What the sources say |
|---|---|
| Cystic fibrosis (CF) | Caused by changes in the CFTR gene and inherited in an autosomal recessive pattern: parents who each carry one changed copy typically have no signs. ACOG says all women who are thinking about getting pregnant or are pregnant are offered carrier screening for it. (MedlinePlus Genetics, CF) (ACOG FAQ, 2026) |
| Spinal muscular atrophy (SMA) | Caused by changes in the SMN1 gene; autosomal recessive. ACOG says 1 in 40 to 1 in 60 people are carriers and about 1 in 6,000 to 1 in 10,000 children are born with SMA, and that all women thinking about pregnancy or already pregnant should be offered carrier screening for it. (MedlinePlus Genetics, SMA) (ACOG SMA FAQ, 2025) |
| Hemoglobin conditions (hemoglobinopathies), such as sickle cell disease and thalassemia | Inherited conditions that affect the number or shape of red blood cells. Sickle cell disease is autosomal recessive. ACOG says all women thinking about pregnancy or already pregnant are offered carrier screening for hemoglobinopathies. (ACOG FAQ, 2026) (MedlinePlus Genetics, sickle cell) |
| Fragile X syndrome | Caused by a change in the FMR1 gene on the X chromosome. People with 55 to 200 repeats of a DNA segment in the gene have a premutation; the condition itself involves more than 200. ACOG lists fragile X among the conditions carrier screening is available for, and the ACMG includes FMR1 in the X-linked genes it says should be offered. (MedlinePlus Genetics, fragile X) (ACOG FAQ, 2026) (ACMG, 2021) |
| Tay-Sachs disease | ACOG lists it among the conditions carrier screening is available for. It typically affects people of Eastern or Central European Jewish, French Canadian and Cajun descent, but ACOG notes anyone can have it. (ACOG FAQ, 2026) |
ACOG describes two ways to screen for more conditions. Targeted screening picks conditions based on your ethnicity or family history; a family history of a condition is a reason to screen for it whatever your background. Expanded screening tests many conditions from one sample, without regard to ethnicity, and the company sets the list (the panel), which can include more than 100 conditions. (ACOG FAQ, 2026) ACOG says ethnic-specific, panethnic and expanded screening are all acceptable, and each practice should use one standard approach. (ACOG CO 690, 2017)
The ACMG (2021) sorts screening into tiers by how common carriers are. Tier 1 is cystic fibrosis and spinal muscular atrophy for everyone, plus more after a risk assessment. Tier 2 adds conditions with a carrier frequency of at least 1 in 100. Tier 3 covers conditions with a carrier frequency of 1 in 200 or more, along with a set list of X-linked genes. Tier 4 has no lower limit. (ACMG, 2021) The ACMG notes that the more conditions are screened, the more likely you are to be found a carrier of at least one. (ACMG, 2021)
What the results mean
| Result | What the sources say |
|---|---|
| Not a carrier (negative) | ACOG: the test did not find the gene change for that condition, and once you have been screened for a specific condition you do not need to be screened for it again. The ACMG adds that a negative result greatly reduces, but does not remove, the chance of being a carrier: the remaining (residual) risk is never zero. (ACOG FAQ, 2026) (ACMG, 2021) |
| Carrier (positive) | You carry one copy of a gene change for the condition. ACOG says carriers usually have no symptoms or only mild ones and often do not know. The next step is to offer testing to the reproductive partner. (ACOG FAQ, 2026) (ACOG CO 691, 2017) |
| Both partners are carriers of the same recessive condition | ACOG: for each child there is a 1 in 4 (25%) chance of having the condition and a 1 in 2 (50%) chance of being a carrier. ACOG says genetic counseling should be offered. (ACOG FAQ, 2026) (ACOG CO 691, 2017) |
| One partner is a carrier, the other is not | ACOG: for each child there is a 1 in 2 (50%) chance of being a carrier. For SMA, ACOG says that if the partner has two healthy copies of the SMN1 gene, the chance of a child with SMA is very low. (ACOG FAQ, 2026) (ACOG SMA FAQ, 2025) |
| Carrier of an X-linked condition | The ACMG says some women who carry an X-linked gene change can have signs themselves. For example, some women with an FMR1 premutation are at risk of premature ovarian insufficiency, a condition separate from fragile X syndrome in their sons. MedlinePlus Genetics also links the premutation with fragile X-associated tremor/ataxia syndrome (FXTAS). (ACMG, 2021) (MedlinePlus Genetics, fragile X) |
Residual risk: why a negative result is not a guarantee
Carrier screening will not find everyone at risk for the conditions it checks, and ACOG says people should be told about the residual risk with any result. (ACOG CO 690, 2017) The ACMG says a precise residual risk cannot be given for a panel of many rare conditions, so labs should not report one as a number. A negative result reduces the risk of being a carrier, but the risk is never zero. (ACMG, 2021) In a small number of cases, results can also be wrong: a false negative or a false positive. (ACOG FAQ, 2026)
Why the partner is tested next
If you are found to be a carrier, your reproductive partner should be offered testing so you can get informed genetic counseling. If both of you are carriers of the same condition, genetic counseling should be offered. (ACOG CO 691, 2017) ACOG says the partner most likely to be a carrier is often tested first; if that partner is not a carrier, no more testing is needed. (ACOG FAQ, 2026) The ACMG says the partner's test should sequence the whole gene in which the change was found, not only a short list of variants. (ACMG, 2021)
A carrier result also matters for relatives, who may carry the same change. ACOG says the person should be encouraged to tell their relatives about the risk and that carrier screening is available. (ACOG CO 691, 2017) See screening when you have a family history.
How it differs from NIPT and newborn screening
Carrier testing looks at the parents, to find people who carry one copy of a gene change. Prenatal testing looks for changes in the genes or chromosomes of a fetus. (MedlinePlus Genetics, 2021) Cell-free DNA screening is one of those prenatal tests; see prenatal cell-free DNA screening (NIPT). The ACMG says carrier screening does not replace newborn screening and cannot find gene changes that are new in the child. (ACMG, 2021) For the newborn tests, see newborn screening results.
Is the result private?
ACOG says the Genetic Information Nondiscrimination Act of 2008 (GINA) makes it illegal for most health insurers to require genetic test results or to use them for decisions on coverage or rates, and illegal for employers to discriminate based on genetic information. GINA does not apply to life, long-term care or disability insurance. (ACOG FAQ, 2026)
Where they differ:
- ACOG (US, 2017, with its patient FAQ): cystic fibrosis, hemoglobin conditions and spinal muscular atrophy for all; ethnic-specific, panethnic and expanded screening are all acceptable, and expanded screening does not replace earlier risk-based recommendations. (ACOG FAQ, 2026) (ACOG CO 690, 2017)
- ACMG (US, 2021): offer Tier 3 screening (autosomal recessive conditions with a carrier frequency of 1 in 200 or more, plus a set list of X-linked genes) to all pregnant people and those planning a pregnancy. It does not recommend offering only Tier 1 or Tier 2, because they do not cover all ethnic groups fairly. It says to consider Tier 4 when partners are related (second cousins or closer) or the family or personal history warrants it. (ACMG, 2021)
- Testing the partner: ACOG describes testing one partner first and the other only if needed; the ACMG says that during pregnancy both partners should be offered testing at the same time. (ACOG FAQ, 2026) (ACMG, 2021)
- NHS England: all pregnant women are offered screening for thalassaemia. Screening for sickle cell disease is offered to all pregnant women in high-prevalence areas; in low-prevalence areas a family origin questionnaire is used to see who is likely to be a carrier. The biological father is offered screening if the woman is a carrier. (NHS England, 2024)
- UK National Screening Committee: screening for cystic fibrosis in pregnancy is not recommended (2019 review), and neither is screening for fragile X syndrome during pregnancy (an archived recommendation). (UK NSC, 2019) (UK NSC, fragile X)
Your doctor decides what your result means for you. ACOG says your ob-gyn or a genetic counselor can explain your risk of having a child with the condition. (ACOG FAQ, 2026)
This page does not give treatment or pregnancy advice. If you have an abnormal result, see after an abnormal screening result for questions to ask.
Questions people ask
What is genetic carrier screening?
A genetic test, usually on blood, saliva or a cheek swab, that shows whether you carry a gene change for certain genetic conditions. Done before or during pregnancy, it shows the chance of having a child with one of those conditions. (ACOG FAQ, 2026)
Who is offered carrier screening?
ACOG says all women thinking about getting pregnant or already pregnant are offered screening for cystic fibrosis, hemoglobin conditions and spinal muscular atrophy. The ACMG (2021) says all pregnant people and those planning a pregnancy should be offered its Tier 3 screening, a longer list of conditions. Screening is optional. (ACOG FAQ, 2026) (ACMG, 2021)
When is the best time to have carrier screening?
Before pregnancy, if possible. ACOG and the ACMG both say screening before pregnancy is preferred, but it can also be done during pregnancy. (ACOG CO 691, 2017) (ACMG, 2021)
If I am a carrier, does my partner need testing?
Usually that is the next step. ACOG says the partner most likely to be a carrier is often tested first, and the other partner is tested only if the first is a carrier. The ACMG says that if screening is done during pregnancy, testing both partners at the same time should be offered. (ACOG FAQ, 2026) (ACMG, 2021)
Does a negative carrier screen mean my baby cannot have the condition?
No. The ACMG says a negative result lowers the chance of being a carrier but never to zero, carrier screening checks only a minority of all genetic conditions, and it cannot find gene changes that are new in the child. (ACMG, 2021)
Is carrier screening the same as NIPT?
No. Carrier screening checks the parents for gene changes they could pass on. Prenatal tests look for changes in the genes or chromosomes of the fetus. Cell-free DNA screening (NIPT) is one of those prenatal tests. (MedlinePlus Genetics, 2021)